Skip to main content
Pfizer Ltd. logo

Pfizer Ltd. - Investor Relations & Filings

Listed IPO Jan 1966
Ticker · PFIZER ISIN · INE182A01018 LEI · 335800XKH6F1JFLUBO78 BSE.NS Manufacturing
Open in API
Filings indexed 1,131 across all filing types
Latest filing 2026-03-28 Regulatory Filings
Country IN India
Listing BSE.NS PFIZER · 2 venues

Key figures FY2026

Period ended 2026-03-31 · INR
Headline annual figures for Pfizer Ltd., fiscal year 2026, reported in INR, with the source filing for each figure.
Total Revenues INR 25.20B per the Interim / Quarterly Report filed 2026-05-12
Net Income INR 7.22B per the Interim / Quarterly Report filed 2026-05-12
Total Assets INR 49.22B per the Interim / Quarterly Report filed 2026-05-12
Total Equity INR 42.03B per the Interim / Quarterly Report filed 2026-05-12
Cash from Ops INR 9.68B per the Interim / Quarterly Report filed 2026-05-12

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Pfizer Ltd.

https://www.pfizerltd.co.in/

Pfizer Ltd. is a leading biopharmaceutical company focused on the discovery, development, and manufacture of innovative healthcare products. The company offers a diverse portfolio of medicines and vaccines across several therapeutic areas, including oncology, inflammation and immunology, rare diseases, internal medicine, and anti-infectives. Key products include advanced treatments for cardiovascular health, respiratory conditions, and various infectious diseases. Pfizer Ltd. leverages global research and development capabilities to provide high-quality, science-based solutions aimed at improving patient outcomes and addressing unmet medical needs. The company maintains a significant presence in the market through its commitment to scientific excellence and a robust pipeline of next-generation therapies.

Recent filings

Filing Released Lang Actions
The trading window for trading in shares of the Company shall remain closed from Tuesday, March 31, 2026 (close of business) till 48 hours after financial results are made public.
Regulatory Filings Classification · 95% confidence The document is a letter from Pfizer Limited addressed to stock exchanges informing about the closure of the trading window for the purpose of declaration of financial results for the quarter and financial year ending March 31, 2026. It is a short notice about trading restrictions around the financial results announcement, not the financial results themselves or any detailed report. The document length is only 1468 characters, indicating it is a brief announcement. There is no financial data, no detailed report, no presentation, or voting results. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement to the stock exchanges about trading restrictions, which is a regulatory requirement but not a financial report or detailed filing.
2026-03-28 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice from Pfizer Limited informing stock exchanges about the closure of the trading window for the purpose of declaration of financial results for the quarter and financial year ending March 31, 2026. It does not contain any financial data or results itself, nor does it present a report. The document is an announcement related to the timing of trading restrictions around the financial results release. Given the short length (1468 characters) and the nature of the content, this fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Interim Report.
2026-03-28 English
Outcome of Board Meeting
Earnings Release Classification · 100% confidence The document is an official announcement from Pfizer Limited regarding its unaudited financial results for the quarter and nine months ended December 31, 2025. It includes a cover letter to stock exchanges, a Limited Review Report from the statutory auditors (B S R & Co. LLP), and detailed financial tables (income statement). Since this document contains the actual financial results and the auditor's review report for an interim period, it is classified as an Earnings Release (ER), which covers quarterly financial results announcements. 9M 2026
2026-02-09 English
Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for ....
Interim / Quarterly Report Classification · 100% confidence The document is a formal submission of unaudited financial results for the quarter and nine months ended December 31, 2025, as required by SEBI regulations. It includes the financial statements (income and expenses table) and the Limited Review Report from the statutory auditors. Since it contains substantive financial data for an interim period (quarterly/nine-month), it is classified as an Interim/Quarterly Report. 9M 2026
2026-02-09 English
Newspaper Advertisement for re-lodgement of Transfer and Dematerialisation of Physical Securities.
Interim / Quarterly Report Classification · 95% confidence The document contains multiple notices and announcements related to corporate actions such as a special window for re-lodgement of transfer and dematerialisation of physical securities, notices about unclaimed dividends and shares transfer to the Investor Education and Protection Fund (IEPF), and financial results extracts for quarters and nine months ended December 31, 2025. The document includes detailed financial data for interim periods (quarter and nine months), with figures for total income, net profit, earnings per share, and other financial ratios. The presence of detailed financial results for a period shorter than a full fiscal year, along with notes on accounting standards and regulatory compliance, indicates this is a comprehensive interim/quarterly financial report. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2026
2026-02-05 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document contains multiple notices and financial information excerpts. The key elements include: 1) Notices about a special window for re-lodgement of transfer and dematerialisation of physical securities by Pfizer Limited and Rain Industries Limited, which are regulatory compliance announcements related to share transfers and dematerialisation. 2) Extracts of standalone and consolidated unaudited financial results for quarters and nine months ended December 31, 2025, for Sammaan Capital Limited and Nomura Capital (India) Private Limited. These financial results include key financial metrics, ratios, and earnings per share, and are described as "extracts" and "unaudited". 3) The document includes statements that the full detailed financial results are available on company websites and stock exchange websites, indicating this document is a summary or extract rather than a full report. 4) The document is about 15,000 characters, which is substantial but the content is mostly notices and extracts rather than a full comprehensive financial report. 5) The financial results are described as "extracts" and "unaudited" and are in compliance with SEBI regulations for quarterly financial results. This matches the characteristics of an Interim / Quarterly Report (IR) which contains substantive financial data and analysis for a period shorter than a full fiscal year. 6) The notices about share transfer windows and dematerialisation are regulatory announcements but do not constitute a full report themselves. The main substantive financial content is the quarterly financial results extracts. Therefore, the best classification is Interim / Quarterly Report (IR). 9M 2026
2026-02-05 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.